Market Overview

UPDATE: Credit Suisse Downgrades Infinity Pharmaceuticals on Limited Clinical News in 2014

Related INFI
Benzinga's Top Upgrades
JMP Securities Upgrades Infinity Pharmaceuticals To Market Outperform

In a report published Thursday, Credit Suisse analyst Jason Kantor downgraded the rating on Infinity Pharmaceuticals (NASDAQ: INFI) from Outperform to Neutral, but reiterated the $20.00 price target.

In the report, Credit Suisse noted, “We are downgrading INFI to Neutral because (1) limited clinical data is expected in 2014, (2) an increasingly complex competitive landscape, which we think is evolving to favor BTK inhibitors and ABT-199 over PI3K inhibitors; and (3) risk of class effect safety issues or drug specific safety issues, although initial concerns over infections and liver enzymes seem to have cooled down.”

Infinity Pharmaceuticals closed on Wednesday at $13.31.

Latest Ratings for INFI

DateFirmActionFromTo
Sep 2014JMP SecuritiesUpgradesMarket PerformMarket Outperform
Sep 2014JefferiesMaintainsBuy
Sep 2014WedbushUpgradesUnderperformNeutral

View More Analyst Ratings for INFI
View the Latest Analyst Ratings

Posted-In: Credit Suisse Jason KantorAnalyst Color Downgrades Analyst Ratings

 

Related Articles (INFI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional